|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hidalgo M, Cascinu S, Kleeff J, Labianca
R, Löhr JM, Neoptolemos J, Real FX, Van Laethem JL and Heinemann V:
Addressing the challenges of pancreatic cancer: Future directions
for improving outcomes. Pancreatology. 15:8–18. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Duell EJ, Lucenteforte E, Olson SH, Bracci
PM, Li D, Risch HA, Silverman DT, Ji BT, Gallinger S, Holly EA, et
al: Pancreatitis and pancreatic cancer risk: A pooled analysis in
the international pancreatic cancer Case-control consortium
(PanC4). Ann Oncol. 23:2964–2970. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tumas J, Kvederaviciute K, Petrulionis M,
Kurlinkus B, Rimkus A, Sakalauskaite G, Cicenas J and Sileikis A:
Metabolomics in pancreatic cancer biomarkers research. Med Oncol.
33:1332016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carrato A, Falcone A, Ducreux M, Valle JW,
Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C and
Parthenaki I: A systematic review of the burden of pancreatic
cancer in europe: Real-world impact on survival, quality of life
and costs. J Gastrointest Cancer. 46:201–211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peto R: The fraction of cancer
attributable to lifestyle and environmental factors in the UK in
2010. Br J Cancer. 105 Suppl 2:S12011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hidalgo M: Pancreatic cancer. N Engl J
Med. 362:1605–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ezzati M, Henley SJ, Lopez AD and Thun MJ:
Role of smoking in global and regional cancer epidemiology: Current
patterns and data needs. Int J Cancer. 116:963–971. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Willett WC: Diet and cancer. Oncologist.
5:393–404. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z,
Ma Y, Yu Y, Lin H, Chen AP and Chen CD: JARID1B is a histone H3
lysine 4 demethylase up-regulated in prostate cancer. Proc Natl
Acad Sci USA. 104:19226–19231. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Scibetta AG, Santangelo S, Coleman J, Hall
D, Chaplin T, Copier J, Catchpole S, Burchell J and
Taylor-Papadimitriou J: Functional analysis of the transcription
repressor PLU-1/JARID1B. Mol Cell Biol. 27:7220–7235. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang B, Qi G, Tang F, Yuan S, Wang Z,
Liang X, Li B, Yu S, Liu J, Huang Q, et al: JARID1B promotes
metastasis and epithelial-mesenchymal transition via PTEN/AKT
signaling in hepatocellular carcinoma cells. Oncotarget.
6:12723–12739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benevolenskaya EV: Histone H3K4
demethylases are essential in development and differentiation.
Biochem Cell Biol. 85:435–443. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Barrett A, Madsen B, Copier J, Lu PJ,
Cooper L, Scibetta AG, Burchell J and Taylor-Papadimitriou J: PLU-1
nuclear protein, which is upregulated in breast cancer, shows
restricted expression in normal human adult tissues: A new
cancer/testis antigen? Int J Cancer. 101:581–588. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu PJ, Sundquist K, Baeckstrom D, Poulsom
R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P,
Freemont P and Taylor-Papadimitriou J: A novel gene (PLU-1)
containing highly conserved putative DNA/chromatin binding motifs
is specifically up-regulated in breast cancer. J Biol Chem.
274:15633–15645. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cancer Genome Atlas Network: Comprehensive
molecular portraits of human breast tumours. Nature. 490:61–70.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hayami S, Yoshimatsu M, Veerakumarasivam
A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue
H, et al: Overexpression of the JmjC histone demethylase KDM5B in
human carcinogenesis: Involvement in the proliferation of cancer
cells through the E2F/RB pathway. Mol Cancer. 9:592010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Su Y, Pan J, Zhou Z, Song B, Xiong E
and Chen Z: Connexin 26 is down-regulated by KDM5B in the
progression of bladder cancer. Int J Mol Sci. 14:7866–7879. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shen X, Zhuang Z, Zhang Y, Chen Z, Shen L,
Pu W, Chen L and Xu Z: JARID1B modulates lung cancer cell
proliferation and invasion by regulating p53 expression. Tumour
Biol. 36:7133–7142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohta K, Haraguchi N, Kano Y, Kagawa Y,
Konno M, Nishikawa S, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T, et
al: Depletion of JARID1B induces cellular senescence in human
colorectal cancer. Int J Oncol. 42:1212–1218. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roesch A, Vultur A, Bogeski I, Wang H,
Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA,
Philipp SE, et al: Overcoming intrinsic multidrug resistance in
melanoma by blocking the mitochondrial respiratory chain of
slow-cycling JARID1B(high) cells. Cancer Cell. 23:811–825. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Catchpole S, Spencer-Dene B, Hall D,
Santangelo S, Rosewell I, Guenatri M, Beatson R, Scibetta AG,
Burchell JM and Taylor-Papadimitriou J: PLU-1/JARID1B/KDM5B is
required for embryonic survival and contributes to cell
proliferation in the mammary gland and in ER+ breast cancer cells.
Int J Oncol. 38:1267–1277. 2011.PubMed/NCBI
|
|
24
|
Yamane K, Tateishi K, Klose RJ, Fang J,
Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P
and Zhang Y: PLU-1 is an H3K4 demethylase involved in
transcriptional repression and breast cancer cell proliferation.
Mol Cell. 25:801–812. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wen M, Kwon Y, Wang Y, Mao JH and Wei G:
Elevated expression of UBE2T exhibits oncogenic properties in human
prostate cancer. Oncotarget. 6:25226–25239. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang
P, He X, Wang Q, Huang Y, Jen KY, et al: CUL4A induces
epithelial-mesenchymal transition and promotes cancer metastasis by
regulating ZEB1 expression. Cancer Res. 74:520–531. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang H, Quah SY, Dong JM, Manser E, Tang
JP and Zeng Q: PRL-3 down-regulates PTEN expression and signals
through PI3K to promote epithelial-mesenchymal transition. Cancer
Res. 67:2922–2926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim SR, Lee KS, Park SJ, Min KH, Lee KY,
Choe YH, Lee YR, Kim JS, Hong SJ and Lee YC: PTEN down-regulates
IL-17 expression in a murine model of toluene diisocyanate-induced
airway disease. J Immunol. 179:6820–6829. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ji S, Qin Y, Shi S, Liu X, Hu H, Zhou H,
Gao J, Zhang B, Xu W, Liu J, et al: ERK kinase phosphorylates and
destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell
Res. 25:561–573. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang L, Yang H, Abel EV, Ney GM, Palmbos
PL, Bednar F, Zhang Y, Leflein J, Waghray M, Owens S, et al: ATDC
induces an invasive switch in KRAS-induced pancreatic
tumorigenesis. Genes Dev. 29:171–183. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liou GY, Döppler H, Necela B, Edenfield B,
Zhang L, Dawson DW and Storz P: Mutant KRAS-induced expression of
ICAM-1 in pancreatic acinar cells causes attraction of macrophages
to expedite the formation of precancerous lesions. Cancer Discov.
5:52–63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma Y, Wu Q, Li X, Gu X, Xu J and Yang J:
Pancreatic cancer: From bench to bedside. Ann Transl Med.
4:4582016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chicas A, Kapoor A, Wang X, Aksoy O,
Evertts AG, Zhang MQ, Garcia BA, Bernstein E and Lowe SW: H3K4
demethylation by Jarid1a and Jarid1b contributes to
retinoblastoma-mediated gene silencing during cellular senescence.
Proc Natl Acad Sci USA. 109:8971–8976. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kano Y, Konno M, Ohta K, Haraguchi N,
Nishikawa S, Kagawa Y, Hamabe A, Hasegawa S, Ogawa H, Fukusumi T,
et al: Jumonji/Arid1b (Jarid1b) protein modulates human esophageal
cancer cell growth. Mol Clin Oncol. 1:753–757. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lu W, Liu S, Li B, Xie Y, Adhiambo C, Yang
Q, Ballard BR, Nakayama KI, Matusik RJ and Chen Z: SKP2
inactivation suppresses prostate tumorigenesis by mediating JARID1B
ubiquitination. Oncotarget. 6:771–788. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo
C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC and Zheng
B: Phenformin enhances the therapeutic benefit of BRAF(V600E)
inhibition in melanoma. Proc Natl Acad Sci USA. 110:18226–18231.
2013. View Article : Google Scholar : PubMed/NCBI
|
